Record Details

Embelin - a drug of antiquity: shifting the paradigm towards modern medicine

DSpace at IIT Bombay

View Archive Info
 
 
Field Value
 
Title Embelin - a drug of antiquity: shifting the paradigm towards modern medicine
 
Creator POOJARI, R
 
Subject embelin
ethnomedicinal uses
molecular targets
pharmacotherapeutics
vidanga
X-LINKED INHIBITOR
NITROSODIETHYLAMINE/PHENOBARBITAL-INDUCED-HEPATOCARCINOGENESIS
PEG-DERIVATIZED EMBELIN
BREAST-CANCER CELLS
NF-KAPPA-B
APOPTOSIS PROTEIN
MITOCHONDRIAL PATHWAY
LIPID-PEROXIDATION
WISTAR RATS
IN-VITRO
 
Description Introduction: Embelia ribes or Embelia tsjeriam-cottam, more commonly known as vidanga, is a type of ayurvedic medicine that has been used to treat various diseases for a number of years. Bright orange embelin-rich fruits have been well established as ethnomedicinals, for a number of years with their pharmacological actions attributed to their hydroxybenzoquinone active constituent. Embelin has become known specifically for its antihelminthic and contraceptive use. Areas covered: This drug evaluation provides a historical summary of embelin along with its therapeutic use, phytochemistry and toxicology. Embelin's pharmacotherapeutical properties are also discussed along with its molecular targets. It is hoped that this article will help to draw the attention of researchers and biopharmaceutical companies to the untapped potential in bioprospection for the development of new drugs. Expert opinion: Embelin is the only known non-peptide small-molecule X-linked inhibitor of the apoptosis protein (XIAP) - an anti-apoptotic protein considered a promising cancer therapeutic target. Embelin acts as an NF-kappa B blocker and potential suppressor of tumorigenesis. It also exhibits potent cytotoxic, antioxidant and cancer chemopreventive effects. Given the potential uses of embelin, it is recommended that further investigations take place to properly explore its pharmacological and clinical effects.
 
Publisher INFORMA HEALTHCARE
 
Date 2014-12-28T15:02:54Z
2014-12-28T15:02:54Z
2014
 
Type Article
 
Identifier EXPERT OPINION ON INVESTIGATIONAL DRUGS, 23(3)427-444
1354-3784
1744-7658
http://dx.doi.org/10.1517/13543784.2014.867016
http://dspace.library.iitb.ac.in/jspui/handle/100/16822
 
Language English